“…Tacrolimus is the most widely used calcineurin inhibitor for the prevention of allograft rejection. [5] It may reduce IRI by altering hepatic microcirculation, and it may also promote maintenance of microcirculation in the face of the normally deleterious reperfusion by suppressing endothelial expression of the potent vasoconstrictor endothelin-1. [6,7] More importantly, tacrolimus was demonstrated to effectively ameliorate IRI through the preservation of cytosolic and extracellular glutathione (GSH) [8] that could be regarded as endogenous defence system against ROS.…”